Search
                    Pennsylvania Paid Clinical Trials
A listing of 3293  clinical trials  in Pennsylvania  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            2785 - 2796 of 3293
        
                Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Open vs. Blind Weighing Study In Adolescents and Young Adult With Eating Disorders
                                
            
            
        Recruiting
                            
            
                Current treatments for adolescents and young adults (AYAs) with eating disorders (EDs) do not effectively address a central ED symptom - anxiety about weight gain - which contributes to poor outcomes. The proposed study evaluates the feasibility, acceptability, efficacy, and underlying mechanisms of an enhanced version of "open weighing," a cognitive-behavioral intervention designed to target anxiety about weight gain in AYAs with EDs. Understanding how to better treat AYAs with EDs, and identif...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 12 years and 24 years
            Trial Updated:
                11/18/2024
            
            Locations: 905 W Govener Rd, Hershey, Pennsylvania         
        
        
            Conditions: Eating Disorders, Anorexia Nervosa
        
            
        
    
                
                                    Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
                                
            
            
        Recruiting
                            
            
                This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/18/2024
            
            Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania         
        
        
            Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
        
            
        
    
                
                                    Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
                                
            
            
        Recruiting
                            
            
                TRICS-IV is an international, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in moderate to high risk patients who are 65 years of age or younger undergoing cardiac surgery on cardiopulmonary bypass, using a superiority trial design.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                11/18/2024
            
            Locations: Thomas Jefferson University, Philadelphia, Pennsylvania         
        
        
            Conditions: Disorder, Heart, Postoperative, Cardiac Surgery
        
            
        
    
                
                                    Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops
                                
            
            
        Recruiting
                            
            
                Brief Summary: Nonimmune hydrops fetalis (NIHF) is a potentially fatal condition characterized by abnormal fluid accumulation in two or more fetal compartments. Numerous etiologies may lead to NIHF, and the underlying cause often remains unclear (1). The current standard of genetic diagnostic testing includes a fetal karyotype and chromosomal microarray (CMA), with an option to pursue single gene testing on amniocytes collected by amniocentesis (2). A large subgroup of the NIHF causes includes s...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 16 years and 55 years
            Trial Updated:
                11/18/2024
            
            Locations: Thomas Jefferson University, Philadelphia, Pennsylvania         
        
        
            Conditions: Genetic Disorders, Nonimmune Fetal Hydrops, Nonimmune Hydrops in Neonate
        
            
        
    
                
                                    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
                                
            
            
        Recruiting
                            
            
                This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.
It also contains a sub-study to enroll patients with severe COVID-19.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                11/18/2024
            
            Locations: University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
        
            
        
    
                
                                    Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
                                
            
            
        Recruiting
                            
            
                Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 90 years
            Trial Updated:
                11/18/2024
            
            Locations: University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
        
            
        
    
                
                                    Utilizing Electronic Clinical Decision Support to Enhance mTBI Care at the Primary Care Point of Entry
                                
            
            
        Recruiting
                            
            
                Six primary care practices within a large Philadelphia pediatric care network will use an electronic Clinical Decision Support (eCDS) tool as standard care for concussion evaluation. The eCDS tool will include a prediction rule for children aged 5-18 assessed for mild traumatic brain injury (mTBI). The eCDS tool predicts risk for persistent symptoms and prompts referral to specialty care for those deemed high risk. This research proposes to analyze the clinical and process outcomes in these six...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 5 years and 18 years
            Trial Updated:
                11/15/2024
            
            Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania         
        
        
            Conditions: Brain Concussion, Mild Traumatic Brain Injury
        
            
        
    
                
                                    Understanding Patient Preference on Colorectal Cancer Screening Options-PSU
                                
            
            
        Recruiting
                            
            
                There are significant barriers to colorectal cancer screening within underserved populations due to the cost, accessibility, and acceptability of screening methods. Patient-friendly approaches that minimize stress and discomfort for the patient are needed to enhance screening compliance and achieve an early diagnosis. The primary aim of this study is to examine whether the availability of a blood-based screening option, which can be done at the point of service and is familiar to patients, will...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 45 years and 75 years
            Trial Updated:
                11/15/2024
            
            Locations: Penn State College of Medicine, Hershey, Pennsylvania         
        
        
            Conditions: Colo-rectal Cancer
        
            
        
    
                
                                    PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
                                
            
            
        Recruiting
                            
            
                This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 65 years
            Trial Updated:
                11/15/2024
            
            Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania         
        
        
            Conditions: Focal Segmental Glomerulosclerosis
        
            
        
    
                
                                    The Myelin Disorders Biorepository Project
                                
            
            
        Recruiting
                            
            
                The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.
Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies,...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                11/15/2024
            
            Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania         
        
        
            Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, Aicardi Goutieres Syndrome, Metachromatic Leukodystrophy, TUBB4A-Related Leukodystrophy, 4H Syndrome, Krabbe Disease, Alexander Disease, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Adrenomyeloneuropathy, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy With Subcortical Cysts, Vanishing White Matter Disease, Cockayne Syndrome, Labrune Syndrome, ADLD, Gangliosidoses, Peroxisomal Biogenesis Disorder, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, AGS, Alexanders Leukodystrophy, AxD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, GALC Deficiency, Globoid Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, MLD, PMD, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, GM2 Gangliosidosis, BPAN, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
        
            
        
    
                
                                    Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.             
        
        
    Gender:
                ALL
            Ages:
                30 years and above
            Trial Updated:
                11/14/2024
            
            Locations: University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
        
            
        
    
                
                                    Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
                                
            
            
        Recruiting
                            
            
                This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/14/2024
            
            Locations: UPMC Hillman Cancer Center Erie, Erie, Pennsylvania         
        
        
            Conditions: Refractory Differentiated Thyroid Gland Carcinoma
        
            
        
    